Ontology highlight
ABSTRACT: Importance
Cardiovascular death remains the leading cause of mortality in patients with type 2 diabetes (T2D). A better understanding of the current use and adoption of glucose-lowering drugs with cardiovascular benefit can inform state policies to ensure their appropriate use in patients with T2D.Objective
To characterize the use of glucose-lowering agents with known cardiovascular benefit over time and across states.Design, setting, and participants
This cross-sectional pharmacoepidemiological study of Medicaid prescription rates of glucose-lowering agents with known cardiovascular benefit vs those with less well-established cardiovascular benefit was conducted between 2014 and 2019. In 50 states and the District of Columbia, the study focused on nonmetformin, non
SUBMITTER: Zhai MZ
PROVIDER: S-EPMC9644265 | biostudies-literature | 2022 Nov
REPOSITORIES: biostudies-literature